Technology evaluation: huN901-DM1 (ImmunoGen).
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Thomson Reuters
Abstract
ImmunoGen is developing huN901-DMI, a compound comprised of a CD56-targeted humanized N901 antibody conjugated to the company's proprietary cytotoxic agent. DM1, using its tumor-activated prodrug technology, for the potential treatment of cancers that express CD56, in particular, small-cell lung cancer. © 2005, Thomson Reuters
Description
Keywords
Citation
Smith, S. V. (2005). Technology evaluation: huN901-DM1 (ImmunoGen). Current Opinion in Molecular Therapeutics, 7(4), 394-401.